Telix Pharmaceuticals |
Market Cap (5-Oct) $5,151,129,600 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (29-Sep) 36,267,030 (10.67%) (12th) |
|
52w High $18.22 |
52w Low $8.26 |
P/E 140.85 |
EPS 0.14 |
[ARTICLE] Why this CEO thinks 454pc growth in his company is just the beginning
A news article has been posted about Telix Pharmaceuticals on the AFR. The article was published around , on 13 June 2023 at 5:01am.
Telix Pharmaceuticals has topped the inaugural Financial Review Fast Global list, with offshore revenue driven by the US FDA’s approval for its prostate cancer screening tool.
Read ArticleTLX was $10.28 at the close of trade on 09 June 2023
Find all articles about Telix Pharmaceuticals, including others on the AFR, on the media page.
You must be logged in to post a reply.